A new add-on therapy administered every six months targets key inflammatory pathways in asthma and chronic rhinosinusitis ...

GSK on Tuesday said Japan’s Ministry of Health, Labour and Welfare approved Exdensur, also known as depemokimab, for patients with bronchial asthma whose symptoms cannot be controlled with existing ...

GSK gets an entry in the list with Exdensur (depemokimab), a twice-yearly injectable IL-5 inhibitor for severe asthma, which ...

The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

Lyra Therapeutics is suspending further development of its lead product candidate for the treatment of chronic rhinosinusitis and taking steps to cut costs, including workforce reductions that will ...

We are grateful for the contributions of our employees most of whom will leave Lyra as a result of this decision to discontinue development of LYR-210. Our priority moving forward is to evaluate and ...

Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

Studies show that smell loss with age may reflect more serious underlying problems, and is even linked to how long we're ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Another common reason for nosebleeds is “digital manipulation, which is a nice way of saying nose picking or scratching your nose”, says Loftus. The nose is delicate, and even a light bump or scratch ...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...